Adverum Biotechnologies Announces Participation in Cowen Conference
Adverum Biotechnologies, Inc. (NASDAQ: ADVM), a pioneering clinical-stage company focused on innovative gene therapy solutions for common ocular diseases, has recently disclosed plans to participate in a significant healthcare event at the Cowen 45th Annual Healthcare Life Sciences Conference. This prestigious gathering will take place soon, providing an excellent platform for Adverum to share insights into their advancements in gene therapy.
Details of the Presentation
Scheduled for March 4, the company's presentation is set to begin at 11:50 a.m. ET. This event represents a valuable opportunity for industry stakeholders and investors to learn more about the latest developments from Adverum Biotechnologies. For those interested in accessing the presentation, a webcast will be available via the company's website under the Events and Presentations section.
Webcast Availability
Following the live presentation, a recorded version of the webcast will be accessible on the Adverum website for a minimum of 30 days, allowing audiences to revisit the insights shared during the event. This expanded access reflects Adverum's commitment to transparency and engagement with its stakeholders.
About Adverum Biotechnologies
Adverum Biotechnologies is at the forefront of utilizing gene therapy to transform the treatment landscape for ocular diseases. By leveraging its proprietary intravitreal (IVT) platform, the company is developing innovative therapies aimed at achieving durable outcomes from a single administration, thereby alleviating the need for frequent and invasive ocular injections.
Innovative Therapies in Development
One of the standout candidates in their pipeline is ixoberogene soroparvovec (Ixo-vec, formerly ADVM-022), which is currently being evaluated for its efficacy as a one-time injection for patients suffering from neovascular or wet age-related macular degeneration. The potential of this treatment may offer patients a transformative approach to managing their condition, demonstrating both the innovation and dedication of Adverum to advancing ocular health.
A Vision for the Future
With the prevalent challenges posed by disabling ocular diseases, Adverum strives to challenge the existing treatment paradigms. Their vision extends beyond mere treatment; the company aspires to establish a new standard of care, optimizing patient outcomes and societal impacts globally. The transformative potential of gene therapy is a testament to the forward-thinking approach embraced by Adverum Biotechnologies.
Commitment to Patient Care
Adverum's overarching mission revolves around the idea of restoring vision and preventing blindness for countless individuals worldwide. By focusing on the evolution of their therapeutic options, the company aims to make a meaningful difference in the lives of those affected by these conditions. Their work not only seeks to improve health outcomes but also endeavours to enhance patients' quality of life.
Contacts for More Information
For any inquiries related to investor relations, interested parties can reach out to Adverum Biotechnologies directly:
Adverum Investor Relations
Email: ir@adverum.com
Frequently Asked Questions
What is the Cowen Annual Healthcare Conference?
The Cowen Annual Healthcare Conference is a prominent event where leading biotech and healthcare companies present their developments and insights to investors and industry experts.
What does Adverum Biotechnologies specialize in?
Adverum Biotechnologies specializes in gene therapy, focusing specifically on developing innovative treatments for prevalent ocular diseases.
What is ixoberogene soroparvovec?
ixoberogene soroparvovec, also known as Ixo-vec, is a gene therapy candidate being developed by Adverum for treating wet age-related macular degeneration.
How can I access the presentation?
The presentation can be accessed through the Events and Presentations section of Adverum's website, and a replay will be available for 30 days post-event.
What is Adverum's mission?
Adverum's mission is to establish gene therapy as the standard of care for ocular diseases, helping to preserve vision and improve patients' lives globally.
